Clinical Trial Update: F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating F16IL2 plus paclitaxel in metastatic Merkel cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma

Drugs mentioned

• F16IL2 (F16-IL2)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Philogen S.p.A. | Conditions: Merkel Cell Carcinoma | Phase 2 | Status: TERMINATED